-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: AML is a cloned proliferative disease of bone marrow, the most common leukemia in China, about 1.62 to 2.32 people / 100,000 people.
Axa Pharma announced today that the company has completed the first phase Ib clinical study of a new class 1 drug MDM2-p53 inhibitor APG-115 as a single drug and a combination of treatments for adult recurrence or difficult treatment of acute myeloid leukemia (AML), recurrence or progression of high-risk/extremely high-risk bone marrow hyperplasia syndrome (MDS), and has completed the first patient administration in China.
as the first MDM2-p53 inhibitor to enter clinical phase in China for the treatment of solid tumors, this is the first clinical study of APG-115 to engage in blood tumor indications.
the study as a national multicenter Ib clinical study designed to assess the safety, pharmacokinetics, and pharmacodynamics characteristics of patients with blood tumors such as APG-115 as a single and aarnucleocosine or aglycosine treatment for recurrence or difficult treatment of AML, recurrence or progression of high-risk/extremely high-risk MDS.
AML is a cloned proliferative disease of bone marrow, the incidence increases with age, is the most common leukemia in China, about 1.62 to 2.32 people / 100,000 people.
treatment for AML has been based on a "7-plus-three" combination (7-day glycosine plus 3-day cycloidal drugs) as the standard induction therapy, but up to 40% of newly diagnosed AML patients are still unable to achieve full remission (CR), i.e. incurable, or relapse within 6 months of obtaining CR.
MDS is a group of heterogeneous hematopoietic diseases derived from abnormally pluripotent stem cells, characterized by low hematopoietic function, bone marrow failure, reduction of peripheral blood cells and decreased survival rate.
in China, the incidence of MDS is about 5 per 100,000 people.
demethylation drugs have a high response rate for Treatment of MDS, many patients end up developing resistance to the effects of demethylated drugs.
once drug resistance occurs, the overall prognosis becomes very poor.
in high-risk MDS patients, the failure of demethylation drugs was associated with an average survival of less than 6 months.
so there is an urgent need for new treatments and more effective treatments for AML or MDS patients with relapse progression.
APG-115 is an oral bioavailable, highly selective small molecule MDM2 inhibitor in The Pharmaceuticals of Axa, which has a high binding affinity for MDM2 and restores p53 tumor inhibition by blocking MDM2-p53 interactions.
APG-115 has previously conducted a number of clinical studies in China and the United States to treat solid tumors, and is the first MDM2-p53 inhibitor to enter a clinical phase in China.
is currently working on the global clinical development of a number of APG-115 blood tumor indications. "There is still a large and unmet clinical need for the treatment of blood tumors such as AML and MDS, " said Dr. Yifan Yin Yifan, Chief Medical Officer of
Axa.
we also note that the development of drugs targeting MDM2-p53 is receiving increasing attention from the industry. As
the first MDM2-p53 inhibitor to enter clinical phase in China, aPG-115 has shown good safety and initial efficacy in clinical studies on solid tumors.
we will further explore the potential of APG-115 in blood tumors to provide more treatment options for AML and MDS patients in China and around the world.
" References s1 ChangR, WuS, ChenW, etal. Analysisondresofleukemia Gansu Province from 2003to 2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ModernMarchMed.2014; 41 (21): 3841-04.[2] TholF, Schlenk RF, Heuser M, Ganser A.2015.HowItreatrefractoryanderelaps edacutemyeloidle.Blood126:319-27 GorebetT, SSD, EsterniB, Gardin C, Itzykson R, etal.2011.Outcomeofhigh-riskmyelodysafter plastic syndrome Azacitidinetreatmentfailure.JClin Oncol29:3322-7.